Ceftiofur

Bacterial respiratory and digestive tract infections in livestock and poultry have long been the key and difficult points for prevention and control at the breeding end. As the first third-generation cephalosporin antibiotic exclusively for animals, ceftiofur exerts a rapid bactericidal effect by inhibiting the synthesis of bacterial cell walls, and has strong antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria. It is mainly clinically used for the treatment of diseases such as bacterial respiratory tract infections in livestock and poultry including pigs, cattle and chickens, dairy cow mastitis, and yellow and white scour of piglets. With the advantages of wide antibacterial spectrum, few allergic reactions and strong tissue penetration, it is one of the core categories of anti-infective drugs for large-scale breeding.

The current global ceftiofur market size is approximately USD 320 million, with an annual compound growth rate maintained at around 4.8%. The growth momentum mainly comes from the increase in the scale rate of global livestock and poultry breeding and the policy drive of standardized use of veterinary antibacterial drugs. As a core producer of ceftiofur, China accounts for more than 70% of the total global supply capacity. Affected by the advancement of the centralized drug procurement policy for veterinary drugs and the recovery of prosperity in the breeding end in the domestic market, the overall market size of domestic ceftiofur API and preparations exceeded RMB 1.2 billion in 2023, among which generic preparations accounted for more than 95%, and the market competition is concentrated among leading compliant manufacturers.

The original research enterprise of ceftiofur is Pfizer Inc. of the United States, with the original brand name "Excenel", and its core compound patent expired globally in 2005. The main dosage forms approved for the original research include ceftiofur sodium for injection and ceftiofur hydrochloride injection, with common specifications of 0.1g, 0.5g, 1g and 100ml:5g. The original preparation has been included in the FDA Reference Listed Drug Catalog, and it is also listed as a reference preparation for veterinary chemical drugs in China. At present, more than 30 domestic enterprises have obtained A status for their ceftiofur APIs through CDE registration, and the number of approval documents for domestic preparations such as ceftiofur sodium and ceftiofur hydrochloride exceeds 200, which can fully meet the drug demand of the domestic breeding end. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for ceftiofur API, with most products in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable material basis support for the quality research and compliance declaration of veterinary drug R&D enterprises and API manufacturers.